Back to search results

A Study of BGB-11417 in Participants With Myeloid Malignancies

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Acute Myeloid Leukemia · Myelodysplastic Syndromes · Myelodysplastic/Myeloproliferative Neoplasm

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • City of Hope National Medical Center, Duarte, California, United States

  • Tampa General Hospital, Tampa, Florida, United States

  • Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh, Pennsylvania, United States

  • Md Anderson Cancer Center, Houston, Texas, United States

  • Medical College of Wisconsin, Milwaukee, Wisconsin, United States

  • Concord Repatriation General Hospital, Concord, New South Wales, Australia

  • St George Hospital, Kogarah, New South Wales, Australia

  • Orange Health Hospital, Orange, New South Wales, Australia

  • Gold Coast University Hospital, Southport, Queensland, Australia

  • Monash Health, Clayton, Victoria, Australia

  • St Vincents Hospital Melbourne, Fitzroy, Victoria, Australia

  • Austin Health, Heidelberg, Victoria, Australia

  • The Alfred Hospital, Melbourne, Victoria, Australia

  • Fiona Stanley Hospital, Murdoch, Western Australia, Australia

  • Linear Clinical Research, Nedlands, Western Australia, Australia

  • One Clinical Research, Nedlands, Western Australia, Australia

  • Peking University Peoples Hospital, Beijing, Beijing Municipality, China

  • The First Hospital of Lanzhou University, Lanzhou, Gansu, China

  • Guangdong Provincial Peoples Hospital, Guangzhou, Guangdong, China

  • Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

  • The Second Peoples Hospital of Shenzhen, Shenzhen, Guangdong, China

  • Henan Cancer Hospital, Zhengzhou, Henan, China

  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

  • The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

  • The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang, Jiangxi, China

  • West China Hospital, Sichuan University, Chengdu, Sichuan, China

  • Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin Municipality, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

  • Hopital Claude Huriez Chu Lille, Lille, France

  • Hopital Larchet, Nice, France

  • Hopital Saint Louis, Paris, France

  • Universitaetsklinikum Leipzig Aor, Leipzig, Germany

  • Universitaetsklinikum Ulm, Ulm, Germany

  • Policlinico Sorsola Malpighi, Aou Di Bologna, Bologna, Italy

  • Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst, Meldola, Italy

  • Niguarda Cancer Center Division of Hematology, Milan, Italy

  • North Shore Hospital, Auckland, New Zealand

  • Wellington Regional Hospital (Ccdhb), Wellington, New Zealand

  • Samsung Medical Center, GangnamGu, Seoul Teugbyeolsi, South Korea

  • Severance Hospital Yonsei University Health System, SeodaemunGu, Seoul Teugbyeolsi, South Korea

  • Hospital de La Santa Creu I Sant Pau, Barcelona, Spain

  • Hospital Universitario de Salamanca, Salamanca, Spain

  • Hospital Universitario Virgen Del Rocio, Seville, Spain

  • Hospital Universitari I Politecnic La Fe, Valencia, Spain

  • Edinburgh Cancer Centre, Edinburgh, United Kingdom

  • The Christie Hospital, Greater Manchester, United Kingdom

Study leads

  • Study Director

    BeOne Medicines

View source on ClinicalTrials.gov(opens in a new tab)